126 related articles for article (PubMed ID: 31603448)
1. Combretastatin A4 nanodrug combined plerixafor for inhibiting tumor growth and metastasis simultaneously.
Jiang J; Shen N; Song W; Yu H; Sakurai K; Tang Z; Li G
Biomater Sci; 2019 Dec; 7(12):5283-5291. PubMed ID: 31603448
[TBL] [Abstract][Full Text] [Related]
2. A poly(l-glutamic acid)-combretastatin A4 conjugate for solid tumor therapy: Markedly improved therapeutic efficiency through its low tissue penetration in solid tumor.
Liu T; Zhang D; Song W; Tang Z; Zhu J; Ma Z; Wang X; Chen X; Tong T
Acta Biomater; 2017 Apr; 53():179-189. PubMed ID: 28167300
[TBL] [Abstract][Full Text] [Related]
3. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug.
Jiang J; Shen N; Ci T; Tang Z; Gu Z; Li G; Chen X
Adv Mater; 2019 Nov; 31(44):e1904278. PubMed ID: 31549774
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Dipeptidyl Peptidase-4 Accelerates Epithelial-Mesenchymal Transition and Breast Cancer Metastasis via the CXCL12/CXCR4/mTOR Axis.
Yang F; Takagaki Y; Yoshitomi Y; Ikeda T; Li J; Kitada M; Kumagai A; Kawakita E; Shi S; Kanasaki K; Koya D
Cancer Res; 2019 Feb; 79(4):735-746. PubMed ID: 30584072
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
6. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.
Chaudary N; Pintilie M; Jelveh S; Lindsay P; Hill RP; Milosevic M
Clin Cancer Res; 2017 Mar; 23(5):1242-1249. PubMed ID: 27697997
[No Abstract] [Full Text] [Related]
8. Antimetastasis and antitumor efficacy promoted by sequential release of vascular disrupting and chemotherapeutic agents from electrospun fibers.
Luo X; Zhang H; Chen M; Wei J; Zhang Y; Li X
Int J Pharm; 2014 Nov; 475(1-2):438-49. PubMed ID: 25218185
[TBL] [Abstract][Full Text] [Related]
9. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
10. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
[TBL] [Abstract][Full Text] [Related]
12. The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis.
Yan L; Cai Q; Xu Y
Clin Cancer Res; 2013 Sep; 19(17):4706-16. PubMed ID: 23690484
[TBL] [Abstract][Full Text] [Related]
13. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
[TBL] [Abstract][Full Text] [Related]
14. AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.
Liao YX; Fu ZZ; Zhou CH; Shan LC; Wang ZY; Yin F; Zheng LP; Hua YQ; Cai ZD
Oncol Rep; 2015 Jul; 34(1):33-42. PubMed ID: 25997540
[TBL] [Abstract][Full Text] [Related]
15. Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus.
Yu H; Shen N; Bao Y; Chen L; Tang Z
Biomater Sci; 2020 Jan; 8(1):325-332. PubMed ID: 31714543
[TBL] [Abstract][Full Text] [Related]
16. CXCR4 antagonists suppress small cell lung cancer progression.
Taromi S; Kayser G; Catusse J; von Elverfeldt D; Reichardt W; Braun F; Weber WA; Zeiser R; Burger M
Oncotarget; 2016 Dec; 7(51):85185-85195. PubMed ID: 27835905
[TBL] [Abstract][Full Text] [Related]
17. CXCR4 regulates growth of both primary and metastatic breast cancer.
Smith MC; Luker KE; Garbow JR; Prior JL; Jackson E; Piwnica-Worms D; Luker GD
Cancer Res; 2004 Dec; 64(23):8604-12. PubMed ID: 15574767
[TBL] [Abstract][Full Text] [Related]
18. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis.
Martinez-Ordoñez A; Seoane S; Cabezas P; Eiro N; Sendon-Lago J; Macia M; Garcia-Caballero T; Gonzalez LO; Sanchez L; Vizoso F; Perez-Fernandez R
Oncogene; 2018 Mar; 37(11):1430-1444. PubMed ID: 29321662
[TBL] [Abstract][Full Text] [Related]
20. Amide-sulfamide modulators as effective anti-tumor metastatic agents targeting CXCR4/CXCL12 axis.
Wu R; Yu W; Yao C; Liang Z; Yoon Y; Xie Y; Shim H; Bai R
Eur J Med Chem; 2020 Jan; 185():111823. PubMed ID: 31698158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
